FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention presents formulations providing the effective delivery of methylnaltrexone compositions. A pharmaceutical composition according to the invention contains an effective amount of methylnaltrexone, calcium ethylenediaminotetraacetic acid (EDTA) or calcium-disodium salt of EDTA and hydrochloride glycine in an aqueous solution. The above solution has pH from approximately 3 to approximately 4. What is also described is a method for preparing the formulation of methylnaltrexone.
EFFECT: composition is characterised by long-storage and severity stability; it ensures preventing, treating, delaying, relieving or reducing a severity of side effects accompanying the administration of analgesic opioids.
30 cl, 4 dwg, 20 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL PREPARATIVE FORM | 2004 |
|
RU2362560C2 |
| TIGECYCLINE COMPOSITION AND METHODS FOR PREPARING | 2006 |
|
RU2428190C2 |
| OXIDATION STABLE AND BREAKING RESISTANCE DOSAGE FORM | 2010 |
|
RU2567723C2 |
| CONCENTRATE OF THERAPEUTIC SOLUTION | 2011 |
|
RU2576026C2 |
| COMPOSITION FOR OPTICAL VISUALIZATION, METHOD OF ITS PRODUCTION AND USE | 2019 |
|
RU2802481C2 |
| APPLICATION OF METHYL NALTREXONE FOR TREATING IRRITABLE COLON SYNDROME | 2004 |
|
RU2373936C2 |
| AQUEOUS COMPOSITION CONTAINING 1-(4-{[4-(DIMETHYLAMINO)PIPERIDINE-1-YL]CARBONYL} PHENYL)-3-[4-(4,6- DIMORPHOLINE-4-YL-1,3,5-TRIAZINE-2-YL)PHENYL]UREA | 2019 |
|
RU2772287C1 |
| COMPOSITIONS AND METHODS OF USING CHOLINE ESTER OF LIPOIC ACID | 2015 |
|
RU2735790C2 |
| PHARMACEUTICAL COMPOSITION | 2011 |
|
RU2604690C2 |
| PHARMACEUTICAL COMPOSITION | 2011 |
|
RU2737264C2 |
